- $304.51m
- $478.50m
- $114.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.27 | ||
| EV to EBITDA | 8.83 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 124.13% | ||
| Return on Equity | n/a | ||
| Operating Margin | 38.79% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 295.67 | 98.02 | 156.31 | 103.46 | 114.2 | 125.2 | 115.88 | 5.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Agenus Inc. is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious disease. The Company's primary business is immuno-oncology, which is advancing antibody-based programs to activate innate and adaptive immunity, overcome tumor immune evasion and expand the population of patients from immunotherapy. Its lead clinical program is botensilimab, alone and in combination with balstilimab, is a clinical-stage immuno-oncology asset which may be used as standalone agents or be complimentary to botensilimab plus balstilimab. Its internal discovery and translation platforms support target identification, antibody generation, biomarker analysis, and candidate selection. The Company's clinical and preclinical portfolio include agents directed to CTLA-4, PD-1, CD137, CD73/TGF-beta, ILT2, LAG-3, TIM-3, and TIGIT, all of which remain as proprietary assets of Agenus.
Directors
- Garo Armen CHM (73)
- Brian Corvese IND (68)
- Jennifer Buell DRC (52)
- Susan Hirsch IND (73)
- Steven O'Day OTH (65)
- Thomas Harrison LED (78)
- Marco Marcucci DRC (55)
- Last Annual
- December 31st, 2025
- Last Interim
- September 30th, 2026
- Incorporated
- November 10th, 1999
- Public Since
- February 4th, 2000
- No. of Shareholders
- 178
- No. of Employees
- 81
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 45,246,510
- Address
- 3 Forbes Rd, LEXINGTON, 02421-7305
- Web
- https://agenusbio.com/
- Phone
- +1 3026587581
- Auditors
- KPMG LLP
Latest News for AGEN
Upcoming Events for AGEN
Q4 2026 Agenus Inc Earnings Release
Similar to AGEN
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
Acurx Pharmaceuticals
NASDAQ Capital Market
FAQ
As of Today at 09:07 UTC, shares in Agenus are trading at $6.73. This share price information is delayed by 15 minutes.
Shares in Agenus last closed at $6.73 and the price had moved by +55.43% over the past 365 days. In terms of relative price strength the Agenus share price has outperformed the S&P500 Index by +38.42% over the past year.
The overall consensus recommendation for Agenus is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreAgenus does not currently pay a dividend.
Agenus does not currently pay a dividend.
Agenus does not currently pay a dividend.
To buy shares in Agenus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.73, shares in Agenus had a market capitalisation of $304.51m.
Here are the trading details for Agenus:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AGEN
Based on an overall assessment of its quality, value and momentum Agenus is currently classified as a Turnaround. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Agenus is $27.00. That is 301.19% above the last closing price of $6.73.
Analysts covering Agenus currently have a consensus Earnings Per Share (EPS) forecast of $0.75 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agenus. Over the past six months, its share price has outperformed the S&P500 Index by +84.05%.
As of the last closing price of $6.73, shares in Agenus were trading +31.71% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Agenus PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.73.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Agenus' management team is headed by:
- Garo Armen - CHM
- Brian Corvese - IND
- Jennifer Buell - DRC
- Susan Hirsch - IND
- Steven O'Day - OTH
- Thomas Harrison - LED
- Marco Marcucci - DRC